[Experimental study on prevention and treatment of focal segmental glomerulosclerosis with heparin].
OBJECTIVE
To observe the preventive and therapeutic feasibility of heparin calcium injection in rats with focal segmental glomerulosclerosis (FSGS).


METHODS
Eighteen male Wistar rats were divided into three groups: Normal control group (A, n=6), heparin-treated rats (B, n=6) and model group (C, n=6). Rat model of FSGS was constructed with low-dose adriamycin, metaraminol and high lipid feed method. Group B was treated with heparin. 24-hour urinary protein was measured at the 0, 2nd, 4th, 6th and 12th week. Serum total protein, albumin, cholesterol, blood urea nitrogen (BUN) and serum creatinine (SCr) were determined at 0, 2nd, 6th and 12th week. Renal cortex blood flow was performed at the 12th week. Renal pathology changes were evaluated at the 12th week as well.


RESULTS
24-hour urinary protein was decreased in heparin treatment group after 6th week. The serum cholesterol level in heparin treatment group was lower than that in model group at 12th week. Renal cortex blood flow was increased significantly in heparin -treated group. Glomerular sclerotic index (SI) and glomerular extracellular matrix (ECM)/glomerular area (GA) were decreased significantly in heparin treatment group. Electron microscopy revealed that there was no glomerular capillary cavities obstruction in heparin -treated group, basement membrane change and foot precesses fusion were markedly alleviated in comparison with model group.


CONCLUSIONS
Heparin may be play a valuable role in the prevention and treatment of FSGS.
Zhang
Bi-li
BL
Department of Nephrology, Tianjin Children's Hospital, Tianjin 300074, China.
Li
Zhi-jun
ZJ
Song
Lan-yun
LY
Zhou
Hong
H
Wang
Wen-hong
WH
Zhang
Xuan
X
D000418:Albumins / Q000032:analysis; D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy*; D006493:Heparin / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology / Q000503:physiopathology / Q000648:ultrastructure; D007677:Kidney Function Tests; D008297:Male; D008854:Microscopy, Electron; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D000418:Albumins; D000925:Anticoagulants; D006493:Heparin; D002784:Cholesterol; D003404:Creatinine